Retatrutide is an investigational triple receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, improving blood glucose control and promoting weight loss
Nov 06, 2023, 19:00 ET The ultra-small 1cm patch, which only needs to be applied once a week, dramatically increases user convenience Daewoong Therapeutics employs the 'CLOPAM' platform to develop 'advanced formulations,' with plans for commercialization by 2028 CEO Seung-Ho Jeon states, "By developing the GLP-1 analogue patch-type formulation, we aim to meet the unmet needs of patients and medical professionals." SEOUL, South Korea, Nov
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Most reconstitution charts default to this ratio